CompanyOverview\|NYSE:PFE] A dividend yield that surpasses 7.5% from a pharmaceutical sector giant like Pfizer Inc. (NYSE: PFE) certainly catches the eye of income- ...

Read also: USFDA approves Pfizer Adcetris combination regimen for Relapsed/Refractory Diffuse Large B-Cell Lymphoma The transaction is expected to close in the third quarter subject to fulfillment of ...

The global antibody drug conjugate (ADC) market is thriving, fueled by rising cancer prevalence, technological advancements, and demand for targeted therapies. ADCs, which merge monoclonal antibodies ...

Despite trading near decade-low valuations, Pfizer PFE is strategically repositioning itself for substantial long-term growth through its oncology transformation, particularly via the Seagen ...

SAN DIEGO, May 15, 2025 /PRNewswire/ -- Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, has announced today the formation of its Scientific Advisory ...

based on data from the ongoing phase 3 ECHELON-3 trial (NCT04404283), in which patients have been randomized 1:1 to receive brentuximab vedotin (Adcetris; Seagen)/lenalidomide/rituximab or placebo ...

Brentuximab vedotin (Adcetris, Takeda) is indicated for 'adult patients with previously untreated CD30+ stage III or IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine and ...

Brentuximab vedotin (Adcetris) with doxorubicin, dacarbazine and vinblastine is available on the NHS. It is a possible treatment for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma in adults.

Department of Discovery & Development Technologies, The Healthcare Business of Merck KGaA, Darmstadt 64293, Germany ...

The following are the top rated Health Care stocks according to Validea's Earnings Yield Investor model based on the published strategy of Joel Greenblatt. This value model looks for companies ...

Pfizer is also working on expanding the labels of approved products (oncology as well as non-oncology) like Padcev, Adcetris, Litfulo, Nurtec, Velsipity and Elrexfio, among others. Though Pfizer ...